GLGasper Letnar

Gasper Letnar

*This is an algorithmically generated author record based on publicly available information.

Gasper Letnar has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effect of Virtual Reality–Based Social Cognitive Training for Autistic Adults: Protocol for STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) Randomized Clinical Trial

    by Johannes Andresen, Alberte C E Jeppesen, Anne Sofie Due, Lise Sandvig Mariegaard, Rizwan Parvaiz, Carsten Hjorthøj, Amy Elizabeth Pinkham, Merete Nordentoft, Gasper Letnar, Jens Richardt Møllegaard Jepsen, et al.

    Background: Autistic adults constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in autistic adults have shown promising results. Recent studies investigating the effect of virtual reality (VR)–based interventions for autistic adults have provided preliminary evidence supporting the feasibility and effectiveness of using this innovative technology. These studies indicate that VR interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large-scale randomized clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for autistic adults. Objective: This protocol aims to provide a comprehensive description of the design and methodology of the STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) trial. Methods: STEPS is a clinical, randomized, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either virtual reality–based social cognitive training (VRSCT) + treatment as usual (TAU) or TAU alone. The experimental group will receive 12 weekly 1-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises 3 core modules, namely emotions, social understanding, and complex social interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post baseline), and at 6 months post baseline. Results: Participant enrollment began in May 2024. As of February 2025 (initial manuscript submission), 34 participants had been enrolled, increasing to 97 participants as of December 2025. Completion of enrollment is expected in April 2026. Data analysis is expected to begin in October 2026 following the final 6-month follow-up assessment. Results are anticipated in December 2026 and will be disseminated through peer-reviewed publications. Conclusions: To our knowledge, STEPS is the hitherto largest randomized clinical trial globally investigating the effect of VRSCT for autistic adults. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, and co-occurring clinical symptoms, and to reduce social cognitive deficits in autistic adults. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments.


  • Open Access

    Impact of an Insulin Bolus Calculator on Glycemic Control in Relation to Exercise—A Crossover Randomized Controlled Trial

    by Kenney Fehrenkamp Pedersen, Pernille Rudebeck Mogensen, Mikkel Thor Olsen, Gaspar Letnar, Maria Amlund Kunckel, Ditte Hjorth Laursen, Peter Lommer Kristensen

    Introduction: Exercise benefits individuals with type 1 diabetes (T1D) but is often hindered by the risk of hypoglycemia. While guidelines provide strategies to mitigate this risk, adherence to recommendations on exercise remains low. Bolus calculators, such as Hedia Diabetes Assistant (HDA), offer a potential way to address this challenge by integrating exercise-related insulin adjustments into daily routines. This trial evaluates the safety and efficacy of HDA in improving glycemic control during exercise. Methods: This randomized, controlled crossover pilot study included 20 adults diagnosed with T1D for >1 year using multiple daily insulin injections and HbA1c between 42 and 72 mmol/mol (6.0–8.6%). Participants were randomized to first use either HDA (arm A) or their habitual diabetes management (arm B) before and after performing a 45-min moderate-intensity session on an exercise bike and subsequently crossover. The primary outcome was change in time in range (TIR) over the two 24 h periods. Results: The mean differences (95% confidence interval [CI]) in TIR and time above range (>10.0 mmol/L) were −2.3% (−13.1%, 8.5%) and 3.93% (−5.7%, 13.5%), respectively, and the median difference in time below range (<3.9 mmol/L) was −0.87% (−2.8%, 0.5%). The incidence rate ratio (95% CI) for total hypoglycemic episodes using HDA was −0.56 (−1.41, 0.29). Safety outcomes revealed fewer adverse events when using HDA. Conclusion: The HDA insulin bolus calculator with an integrated exercise feature appears safe to use when compared with habitual insulin management in people with T1D during moderate-intensity exercise.


  • Ischemic Stroke in Users of Combined Hormonal Contraceptives: A Danish Registry Study

    by Gasper Letnar, Klaus Kaae Andersen, Tom Skyhøj Olsen

    BACKGROUND: The combined hormonal contraceptive (CHC) with ethinylestradiol and progestins is the most widely used contraceptive method among young women and is used by millions worldwide. However, uncertainties exist about the risk of ischemic stroke associated with the use of CHCs with low-dose ethinylestradiol (<50-µg ethinylestradiol) and with the newest fourth-generation progestins that have only been sparsely investigated for the risk of ischemic stroke. METHODS: In this cohort study based on Danish registries covering the entire Danish female population aged 18 to 49 years from 2004 to 2021, we investigated incidence rate ratios (IRRs) of ischemic stroke using CHCs compared with nonuse of hormonal contraceptives. Analyses focused on comparing CHCs based on ethinylestradiol content (30–40- versus ≤20-μg ethinylestradiol), progestin generation (second, third, and fourth) in CHCs, and route of administration (monophasic versus sequential). Poisson regression models adjusting for age, education, ethnicity, calendar year, and medication used for risk factors were utilized. RESULTS: In total, 1 711 757 nonpregnant women contributed 14 697 788 person-years to the investigation. For users of CHCs containing <50-µg ethinylestradiol, the adjusted IRR was increased by 1.77 (95% CI, 1.62–1.93) compared with nonusers of hormonal contraceptives. IRR did not differ between CHCs with 30- to 40- and ≤20-µg ethinylestradiol. Adjusted incidence rate difference between CHC users and nonusers of hormonal contraceptives ranged from 1 in 100 000 women per year in 18 to 24 years of age to 24 in 100 000 women per year in ≥45 years of age. Incidence rate in users of fourth-generation CHCs was 30% lower than that of second-generation CHCs adjusted IRR (0.70 [95% CI, 0.50–0.98]). IRR for users of third-generation CHCs did not differ significantly from that of second-generation users adjusted IRR (1.14 [95% CI, 0.97–1.35]). CONCLUSIONS: Use of CHCs was associated with a 1.77 higher IRR of ischemic stroke. IRR did not relate to ethinylestradiol content in users of CHCs with <50-µg ethinylestradiol. IRR was 30% lower in users of fourth-generation than in users of second-generation CHCs.


  • Risk of Stroke in Women Using Levonorgestrel-Releasing Intrauterine Device for Contraception

    by Gasper Letnar, Klaus Kaae Andersen, Tom Skyhøj Olsen

    BACKGROUND: The commonly used combined hormonal contraceptives with progestins and ethinylestradiol are associated with an increased risk of ischemic stroke (IS). Progestin-only preparations, including levonorgestrel-releasing intrauterine devices (LG-IUDs), are not associated with an increased risk, and in smaller studies, the risk is even reduced. The risk of intracerebral hemorrhage (ICH) has never been investigated. We studied the risk of IS and ICH in women using LG-IUDs compared with women not using hormonal contraceptives. METHODS: In this Danish historical cohort study (2004–2021), we followed nonpregnant women (18–49 years) registering incident IS and ICH in relation to use of LG-IUDs/nonuse of hormonal contraceptives utilizing Danish high-quality registries with nationwide coverage. Poisson regression models adjusting for age, ethnicity, education, calendar year, and medication use for risk factors were applied. RESULTS: A total of 1 681 611 nonpregnant women contributed 11 971 745 person-years (py) of observation. Mean age at inclusion was 30.0 years; mean length of follow-up was 7.1 years; 2916 women (24.4 per 100 000 py) had IS; 367 (3.1 per 100 000 py) had ICH. Of these, 364 784 were users of LG-IUD contributing 1 720 311 py to the investigation; mean age at start of usage was 34.6 years. Nonusers of hormonal contraceptives contributed 10 251 434 py; mean age at inclusion was 30.0 years. The incidence rate of IS/ICH among LG-IUD users was 19.2/3.0 and among nonusers, it was 25.2/3.1 per 100 000 py. After adjustment, incidence rate ratio for IS was 0.78 (CI, 0.70–0.88), and for ICH it was 0.94 (CI, 0.69–1.28). CONCLUSIONS: The use of LG-IUD was associated with a 22% lower incidence rate of IS without raising the incidence rate of ICH. The finding raises the question of whether levonorgestrel, in addition to its contraceptive properties, could have the potential to prevent IS.